Agile Therapeutics Inc financial data

Symbol
AGRX, AGXRW on OTC
Industry
Pharmaceutical Preparations
Location
500 College Road East, Suite 310, Princeton, NJ
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 12, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 53.5 % -36.2%
Quick Ratio 17.1 % +27.6%
Debt-to-equity -180 % +39.2%
Return On Equity 104 % -58.9%
Return On Assets -130 % -0.71%
Operating Margin -62.8 % +72.6%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 6.9M shares +258%
Common Stock, Shares, Outstanding 6.9M shares +321%
Entity Public Float 4.8M USD -66.7%
Common Stock, Value, Issued 5K USD
Weighted Average Number of Shares Outstanding, Basic 6.86M shares +287%
Weighted Average Number of Shares Outstanding, Diluted 6.86M shares +287%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 21.6M USD +32.2%
Cost of Revenue 7.84M USD +6.17%
Research and Development Expense 1.79M USD -31.2%
Selling and Marketing Expense 16M USD -26.1%
General and Administrative Expense 9.5M USD -13.4%
Operating Income (Loss) -13.6M USD +63.8%
Nonoperating Income (Expense) -2.3M USD -113%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -15.9M USD +16.8%
Income Tax Expense (Benefit) -4.68M USD
Net Income (Loss) Attributable to Parent -15.9M USD +16.8%
Earnings Per Share, Basic -0.1 USD/shares -100%
Earnings Per Share, Diluted -0.1 USD/shares -100%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 2.85M USD +2.26%
Accounts Receivable, after Allowance for Credit Loss, Current 4.55M USD +2%
Inventory, Net 5.79M USD +128%
Assets, Current 14.4M USD +24%
Property, Plant and Equipment, Net 27K USD -78.6%
Operating Lease, Right-of-Use Asset 255K USD -54.3%
Other Assets, Noncurrent 238K USD 0%
Assets 15M USD +19%
Accounts Payable, Current 16.5M USD +169%
Employee-related Liabilities, Current 954K USD -57.4%
Accrued Liabilities, Current 9.4M USD +39.3%
Liabilities, Current 26.2M USD +71.3%
Operating Lease, Liability, Noncurrent 100K USD -78.5%
Liabilities 36.9M USD +49.3%
Retained Earnings (Accumulated Deficit) -434M USD -3.79%
Stockholders' Equity Attributable to Parent -21.9M USD -80.8%
Liabilities and Equity 15M USD +19%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -2.48M USD -55.2%
Net Cash Provided by (Used in) Financing Activities 2.54M USD +226%
Net Cash Provided by (Used in) Investing Activities -126K USD -101%
Common Stock, Shares Authorized 300M shares 0%
Common Stock, Shares, Issued 6.9M shares +321%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 59K USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 2.85M USD +2.26%
Interest Paid, Excluding Capitalized Interest, Operating Activities 50K USD -46.8%
Deferred Tax Assets, Valuation Allowance 100M USD +4.05%
Deferred Tax Assets, Gross 100M USD +4.05%
Operating Lease, Liability 289K USD -54.1%
Depreciation 26K USD 0%
Payments to Acquire Property, Plant, and Equipment 126K USD +77.5%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -25.4M USD +64.2%
Lessee, Operating Lease, Liability, to be Paid 300K USD -56.7%
Property, Plant and Equipment, Gross 253K USD 0%
Operating Lease, Liability, Current 289K USD -15.5%
Lessee, Operating Lease, Liability, to be Paid, Year Two 101K USD 0%
Lessee, Operating Lease, Liability, to be Paid, Year One 199K USD -49.9%
Operating Lease, Weighted Average Discount Rate, Percent 0.12 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 11K USD -82.8%
Lessee, Operating Lease, Liability, to be Paid, Year Three 101K USD -74.6%
Deferred Tax Assets, Operating Loss Carryforwards 88.3M USD +1.22%
Preferred Stock, Shares Issued 4.85K shares 0%
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 0 USD
Operating Lease, Payments 87K USD +13%
Additional Paid in Capital 412M USD +1.49%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 284K USD -41.1%
Interest Expense 1.2M USD -54.8%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%